

<b>A</b>	<b>On track, low risk</b>
<b>B</b>	<b>Some concerns, medium risk</b>
<b>C</b>	<b>Significant concerns, high risk</b>

### lifETIME Key Performance Indicators 2019-2023

<b>1</b>	<b>Students Profile</b> To recruit 84 PhD students over five intakes from 2019-2023. Recruited students will have at minimum a 2:1 or higher.	<b>A</b>
	100% of our interdisciplinary projects falling the EPS remit	
<b>2</b>	<b>Centre Quality</b> The CDT will train engineers and scientists to become interdisciplinary innovation leaders in drug discovery and regenerative medicine. Students will complete a skill training programme, developing skills sought after by employers while the centre maintains a high level of student retention.	<b>B</b>
	95% student retention	
	95% student satisfaction with the CDT	
	100% of students publishing (named author) at least one experimental paper as an output from their PhD.	
	100% of students having presented (poster or talk) at least at one established conference	
	100% of students actively undertaking public engagement (blogs, school talks, outreach activities etc)	
	100% of students completing a market assessment, innovation disclosure and the freedom to operate	
	100% of students and staff understanding and promoting sustainability within labs and undertaking at least one positive action defined by LEAF UK (Galway Green Labs, UN Sustainable Goals)	
<b>3</b>	<b>Research</b> To deliver world-class interdisciplinary research through co-created PhD projects between partner universities and stakeholder companies with the overall aim of developing bioengineered humanised 3D models, microfluidics, diagnostics, and sensing platforms to accelerate therapeutic discovery.	<b>A</b>
	100% of UK projects with stakeholder supervision	
	100% of projects working toward the 3Rs (Replacement, Reduction and Refinement)	
<b>4</b>	<b>External engagement</b> To create a UK wide community to develop and grow the non-animal technologies (NAT) sector. The network will provide enhanced networking opportunities for students, academics, stakeholder companies and charities.	<b>B</b>
	CDT will engage with 100% of membership partners	
	Minimum of 25 membership partners	
	Diverse portfolio of MedTech companies, comprising of micro companies, SMEs and MNCs	